Aggrenox Generic Drug Delay Class Action Settlement

UPDATE: Top Class Actions viewers started receiving settlement checks dated Feb. 2, 2021 from the Aggrenox generic drug delay class action settlement worth up to $175.86. Congratulations to everyone who filed a claim and got PAID!

Boehringer Ingelheim and Teva Pharmaceutical, among others, have agreed to pay $54 million to end a class action lawsuit alleging the company delayed the availability of a less-expensive generic version of Aggrenox (aspirin/extended-release dipyridamole), through anticompetitive agreements.

The defendants include Boehringer Ingelheim Pharmaceuticals, Teva Pharmaceuticals USA, Barr Pharmaceuticals, Duramed Pharmaceuticals, and various marketing and other subsidiaries. The Aggrenox class action lawsuit alleges that indirect purchasers of Aggrenox unfairly paid a higher price for the drug when one drug maker, Barr, acquired Teva, stalling the introduction of a generic equivalent onto the market.

Under the terms of the settlement, defendants do not admit any wrongdoing, but will pay $54 million to Class Members, along with attorneys’ fees and other costs.

Class Members include those who purchased or paid for some or all of the purchase price for Aggrenox and/or its generic versions in the Commonwealth of Puerto Rico, Arizona, California, Colorado, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Rhode Island, South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin from Nov. 30, 2009 through Dec. 22, 2017 for consumption by themselves or family.

A second set of Class Members includes those who  paid and/or reimbursed for Aggrenox or generic versions of Aggrenox, in the Commonwealth of Puerto Rico, Arizona, California, Colorado, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon (2010 or after), Rhode Island (purchases after July 15, 2013), South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin for consumption by your members, employees, insured, participants or beneficiaries from Nov. 30, 2009 though Dec. 22, 2017.

Those who want to object or exclude themselves from the terms of the settlement must do so by May 11, 2018.

Who’s Eligible

There are two Classes:

Consumer Class Members include those who “Purchased and/or paid for Aggrenox® or generic versions of Aggrenox®, in the Commonwealth of Puerto Rico, Arizona, California, Colorado, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon (2010 or after), Rhode Island (purchases after July 15, 2013), South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin for consumption by yourself or your family, from November 30, 2009 through December 22, 2017.”

Third-Party Payor Class Members include those who “Purchased, paid and/or reimbursed for Aggrenox® or generic versions of Aggrenox®, in the Commonwealth of Puerto Rico, Arizona, California, Colorado, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas, Maine, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon (2010 or after), Rhode Island (purchases after July 15, 2013), South Dakota, Tennessee, Utah, Vermont, West Virginia, and Wisconsin for consumption by your members, employees, insured, participants or beneficiaries, between November 30, 2009 and December 22, 2017.”

Potential Award

Varies.

Payments will be based on a number of factors, including the number of valid claims filed by all members of the settlement Class and the dollar value of each member of the Class’ purchase(s) in proportion to the total claims filed.

Proof of Purchase

Proof of purchase is not required for the Claim Form; however, the Claims Administrator may ask for additional proof of payment, including receipts, cancelled checks, or credit card statements that show payment for Aggrenox® or generic versions of Aggrenox®.

Claim Form

CLICK HERE TO FILE A CLAIM »

NOTE: If you do not qualify for this settlement do NOT file a claim.

Remember: you are submitting your claim under penalty of perjury. You are also harming other eligible Class Members by submitting a fraudulent claim. If you’re unsure if you qualify, please read the FAQ section of the Settlement Administrator’s website to ensure you meet all standards (Top Class Actions is not a Settlement Administrator). If you don’t qualify for this settlement, check out our database of other open class action settlements you may be eligible for.

Claim Form Deadline

9/14/2018

Case Name

In re: Aggrenox® Antitrust Litigation, Case No. 3:14-md-02516-SRU, in the U.S. District Court for the District of Connecticut

Final Hearing

7/19/2018

UPDATE: On July 19, 2018, the Aggrenox Generic Drug Delay Class Action Settlement was granted final approval by the court.  Please note that claims will not be paid until after the claim deadline passes, and all claims are reviewed and processed. Let Top Class Actions know when you receive a check in the comments section below or on our Facebook page.

UPDATE 2: On August 17, 2018, an appeal to the Aggrenox Generic Drug Delay Class Action Settlement was filed. Claims will not be paid until all appeals are exhausted.  We appreciate your ongoing patience. Top Class Actions will continue to provide updates as we learn more.  

UPDATE: On January 10, 2020, the appeals to the Aggrenox Generic Drug Delay Class Action Settlement were dismissed. It is not known how quickly claims will be paid at this time. Top Class Actions will continue to provide updates as we learn more.  

Settlement Website

www.InReAggrenoxAntitrustLitigation.com

Claims Administrator

Aggrenox Settlement
c/o A.B. Data Ltd.
P.O. Box 173046
Milwaukee, WI 53217
800-494-2165
info@InReAggrenoxAntitrustLitigation.com

Class Counsel

Renae Steiner
HEINS MILLS & OLSON PLC

Marvin A. Miller
MILLER LAW LLC

Steven Shadowen
HILLIARD & SHADOWEN LLP

Defense Counsel

Peter J. Carney
WHITE & CASE LLP

Christopher T. Holding
GOODWIN PROCTER LLP